Details for Patent: 11,590,081
✉ Email this page to a colleague
Which drugs does patent 11,590,081 protect, and when does it expire?
Patent 11,590,081 protects DYANAVEL XR 10, DYANAVEL XR 15, DYANAVEL XR 20, and DYANAVEL XR 5, and is included in one NDA.
Drugs Protected by US Patent 11,590,081
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | DYANAVEL XR 10 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-002 | Nov 4, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | ⤷ Try a Trial | |||
| Tris Pharma Inc | DYANAVEL XR 15 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-003 | Nov 4, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | ⤷ Try a Trial | |||
| Tris Pharma Inc | DYANAVEL XR 20 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-004 | Nov 4, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | ⤷ Try a Trial | |||
| Tris Pharma Inc | DYANAVEL XR 5 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-001 | Nov 4, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
